ELDN (STOCKS)
Eledon Pharmaceuticals, Inc. Common Stock
$3.240000
+0.140000 (+4.52%)
Prev close: $3.100000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- David-Alexandre C. Gros
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $243.48M
- Employees
- 31
- P/E (TTM)
- -5.22
- P/B (TTM)
- 2.88
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Operating Expenses | $83.25M |
| Research and Development | $66.27M |
| Other Operating Expenses | $16.98M |
| Income/Loss From Continuing Operations After Tax | -$45.62M |
| Income/Loss From Continuing Operations Before Tax | -$45.58M |
| Income Tax Expense/Benefit | $35.00K |
| Income Tax Expense/Benefit, Current | $30.00K |
| Income Tax Expense/Benefit, Deferred | $5.00K |
| Net Income/Loss | -$45.62M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$45.62M |
| Net Income/Loss Available To Common Stockholders, Basic | -$42.33M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$3.29M |
| Preferred Stock Dividends And Other Adjustments | -$3.29M |
| Basic Earnings Per Share | -$0.52 |
| Diluted Earnings Per Share | -$0.52 |
| Basic Average Shares | 81,836,246 |
| Diluted Average Shares | 81,836,246 |
| Assets | $169.01M |
| Current Assets | $135.69M |
| Cash | $133.30M |
| Other Current Assets | $2.39M |
| Noncurrent Assets | $33.32M |
| Liabilities | $32.23M |
| Current Liabilities | $18.34M |
| Accounts Payable | $3.63M |
| Other Current Liabilities | $14.72M |
| Noncurrent Liabilities | $13.89M |
| Equity | $81.09M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $81.09M |
| Liabilities And Equity | $169.01M |
| Net Cash Flow From Operating Activities | -$62.34M |
| Net Cash Flow From Operating Activities, Continuing | -$62.34M |
| Net Cash Flow From Investing Activities | $10.79M |
| Net Cash Flow From Investing Activities, Continuing | $10.79M |
| Net Cash Flow From Financing Activities | $53.81M |
| Net Cash Flow From Financing Activities, Continuing | $53.81M |
| Net Cash Flow | $2.26M |
| Net Cash Flow, Continuing | $2.26M |
| Comprehensive Income/Loss | -$45.62M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$45.62M |
| Other Comprehensive Income/Loss | -$2.00K |